WASHINGTON--(BUSINESS WIRE)--The Aplastic Anemia & MDS International Foundation says that data from the AZA-001 clinical trial, published today in The Lancet Oncology, demonstrated that VIDAZA is the only non-transplant treatment that extends survival in higher-risk MDS patients. In the study, VIDAZA was also shown to prevent progression to acute myelogenous leukemia (AML) in patients with MDS. Roughly 30 percent of patients diagnosed with MDS will progress to AML.
